Did you know that HER2 mutations can be found in about 4 percent of patients with non-small cell lung cancer (NSCLC)? Although it’s not a very common genetic event, it’s still important to know how these mutations drive disease progression and how you can treat these NSCLC patients. That’s why Dr. Sandra Misale joins Dr. Hector Chapa to explore the clinical features and characteristics of HER2 mutations along with the available therapeutic options.

As the treatment landscape continues to evolve, what do we need to know about current treatment challenges and novel therapeutic options? Dr. Hector Chapa is joined by Dr. Sandra Misale to explore emerging therapies in HER2-mutated non-small cell lung cancer.

Here to give highlights from the “Finetuning Risk Assessment and Risk Reduction” session at the 2021 San Antonio Breast Cancer Symposium (SABCS) is Dr. Banu Arun, Professor of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center and Executive Director of Cancer Genetics for the MD Anderson Cancer Networks.

FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!

In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don’t have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.

For patients with chronic lymphocytic leukemia, molecular analysis can provide critical information. Dr. John C. Byrd discusses the importance of IGHV and TP53 sequencing and the clinical value they provide.

As the field of chronic lymphocytic leukemia continues to evolve, what we can look forward to seeing at the 63rd American Society of Hematology Annual Meeting and Exposition? Dr. Lindsey Roeker shares what she expects to see at this year’s ASH meeting.

For patients with advanced non-small cell lung cancer, broad molecular testing can be both a solution and a challenge. Here to share key challenges for next-generation sequencing is Dr. Jack West, Associate Clinical Professor at the City of Hope Comprehensive Cancer Center in California.

Has the COVID-19 pandemic limited our treatment options for patients with mantle cell lymphoma? To answer this, Dr. Thomas Kipps reviews key treatment challenges and considerations for these patients amid the ongoing pandemic.

When determining a patient’s therapy regimen, what disease-related factors do we need to keep in mind? Dr. Nicole Lamanna, a Hematologist/Oncologist at Columbia University Medical Center, share strategies for tailoring chronic lymphocytic leukemia treatment and how that can impact patient outcomes.